Here’s what you should know:
1. The FDA approved the first biosimilar, adalimumab-atto, in September 2016.
2. Cyltezo is approved to treat several diseases including: rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
3. Cyltezo is a tumor necrosis factor blocker.
4. Adverse events associated with adalimumab-atto include infections and malignancies. The most common events, however, are infections and injection-site reactions.
More articles on gastroenterology:
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial — 6 insights
Contaminated scopes used in 500+ patients at Buffalo VA
Renewed interest in gastroparesis research brings cure into focus
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
